FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	D.C.	20549
-------------	------	-------

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APP	ROVAL									
OMB Number:	3235-0287									
Estimated average burden										
hours per response:	0.5									

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940 Instruction 1(b).

Name and Address of Reporting Person* Seiser Robert A					<u>A</u>	2. Issuer Name and Ticker or Trading Symbol ACURA PHARMACEUTICALS, INC [ACUR]								neck all appli Directo			10% Ov Other (s	ner	
(Last) (First) (Middle) C/O ACURA PHARMACEUTICALS, INC.						3. Date of Earliest Transaction (Month/Day/Year) 11/20/2023								below)		er & C	below) Controller		
616 N. NORTH COURT, SUITE 120					4. 1	4. If Amendment, Date of Original Filed (Month/Day/Year)								6. Individual or Joint/Group Filing (Check Applicable Line)					
(Street)	NE IL	ı	60067												iled by Mor		orting Persor n One Repor		
(City) (State) (Zip)					Rı	Rule 10b5-1(c) Transaction Indication													
												nade pursua .0b5-1(c). Se		tract, instruction on 10.	on or written	plan th	nat is intended	to	
		Tab	le I - Nor	ı-Deri	vativ	e Se	curities	s Ac	quired,	Dis	osed o	of, or Be	neficia	lly Owned	i				
1. Title of Security (Instr. 3) 2. Transa Date (Month/D					Execution Date			Code (I	Transaction Disposed Code (Instr. 5)		ities Acquired (A) or d Of (D) (Instr. 3, 4 an		Benefici	s Fally (I following (I	Form (D) o	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership		
									Code	v	Amount	(A) o	Price	Transac (Instr. 3	tion(s)			(Instr. 4)	
Common Stock 11/20				0/202	/2023 M ⁽¹⁾ 40,000 A		(2)	438,	438,254(3)		D								
		٦	Fable II - I	Deriva (e.g., p	ative puts,	Seci call	urities . s, warr	Acqı ants	uired, D , option	ispo s, c	sed of, onverti	, or Ben ble secເ	eficiall irities)	/ Owned					
1. Title of Derivative Security (Instr. 3)	Conversion Date or Exercise (Month/Day/Year) if		3A. Deemed Execution I if any (Month/Day	tion Date,		action (Instr.	of		6. Date Exercisable and Expiration Date (Month/Day/Year)			7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction (Instr. 4)	e s Illy	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)	
					Code	v	(A)	(D)	Date Exercisab		Expiration Date	Title	Amount or Number of Shares						
Restricted Stock Unit (2021 Plan)	\$0.01 ⁽²⁾	11/20/2023			M		40,000		(4)		(4)	Common Stock	40,000	(3)	0		D		

Explanation of Responses:

- 1. Represents exchange of restricted stock units.
- 2. Par value of \$.01 must be paid by Reporting Person upon exchange of Restricted Stock Units for stock.
- 3. Not Applicable.
- $4.\ 40,\!000\ Restricted\ Stock\ Units\ were\ granted\ on\ March\ 16,\ 2022\ and\ were\ 100\%\ vested\ on\ December\ 31,\ 2022$

11/20/2023 /s/ Robert A. Seiser

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.